Search

Your search keyword '"Striefler, J.K."' showing total 11 results
Start Over Author "Striefler, J.K."
11 results on '"Striefler, J.K."'

3. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression

Author

Cheung, P.F., Yang, J., Fang, R., Borgers, A., Krengel, K., Stoffel, A., Althoff, K., Yip, C.W., Siu, E.H.L., Ng, L.W.C., Lang, K.S., Cham, L.B., Engel, D.R., Soun, C., Cima, I., Scheffler, B., Striefler, J.K., Sinn, M., Bahra, M., Pelzer, U., Oettle, H., Markus, P., Smeets, E.M.M., Aarntzen, E.H.J.G., Savvatakis, K., Liffers, S.T., Lueong, S.S., Neander, C., Bazarna, A., Zhang, X., Paschen, A., Crawford, H.C., Chan, A.W., Cheung, S.T., Siveke, J.T., Cheung, P.F., Yang, J., Fang, R., Borgers, A., Krengel, K., Stoffel, A., Althoff, K., Yip, C.W., Siu, E.H.L., Ng, L.W.C., Lang, K.S., Cham, L.B., Engel, D.R., Soun, C., Cima, I., Scheffler, B., Striefler, J.K., Sinn, M., Bahra, M., Pelzer, U., Oettle, H., Markus, P., Smeets, E.M.M., Aarntzen, E.H.J.G., Savvatakis, K., Liffers, S.T., Lueong, S.S., Neander, C., Bazarna, A., Zhang, X., Paschen, A., Crawford, H.C., Chan, A.W., Cheung, S.T., and Siveke, J.T.

Abstract

Item does not contain fulltext, Immune evasion is indispensable for cancer initiation and progression, although its underlying mechanisms in pancreatic ductal adenocarcinoma (PDAC) are not fully known. Here, we characterize the function of tumor-derived PGRN in promoting immune evasion in primary PDAC. Tumor- but not macrophage-derived PGRN is associated with poor overall survival in PDAC. Multiplex immunohistochemistry shows low MHC class I (MHCI) expression and lack of CD8(+) T cell infiltration in PGRN-high tumors. Inhibition of PGRN abrogates autophagy-dependent MHCI degradation and restores MHCI expression on PDAC cells. Antibody-based blockade of PGRN in a PDAC mouse model remarkably decelerates tumor initiation and progression. Notably, tumors expressing LCMV-gp33 as a model antigen are sensitized to gp33-TCR transgenic T cell-mediated cytotoxicity upon PGRN blockade. Overall, our study shows a crucial function of tumor-derived PGRN in regulating immunogenicity of primary PDAC.

Published
2022

4. LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group

Author

Perkhofer, L., primary, Striefler, J.K., additional, Sinn, M., additional, Opitz, B., additional, Goetze, T.O., additional, Gallmeier, E., additional, Fischer von Weikersthal, L., additional, Jacobasch, L., additional, Waldschmidt, D., additional, Niedermeier, M., additional, Sohm, M., additional, Sookthai, D., additional, Berger, A., additional, Beutel, A., additional, Seufferlein, T., additional, and Ettrich, T.J., additional

Published
2021
Full Text
View/download PDF

5. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results

Author

Sinn, M., primary, Liersch, T., additional, Riess, H., additional, Gellert, K., additional, Stübs, P., additional, Waldschmidt, D., additional, Lammert, F., additional, Maschmeyer, G., additional, Bechstein, W., additional, Bitzer, M., additional, Denzlinger, C., additional, Hofheinz, R., additional, Lindig, U., additional, Ghadimi, M., additional, Hinke, A., additional, Striefler, J.K., additional, Pelzer, U., additional, Bischoff, S., additional, Bahra, M., additional, and Oettle, H., additional

Published
2020
Full Text
View/download PDF

6. Corrections to “SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study”

Author

Sinn, M., primary, Sinn, B.V., additional, Striefler, J.K., additional, Lindner, J.L., additional, Stieler, J.M., additional, Lohneis, P., additional, Bischoff, S., additional, Bläker, H., additional, Pelzer, U., additional, Bahra, M., additional, Dietel, M., additional, Dörken, B., additional, Oettle, H., additional, Riess, H., additional, and Denkert, C., additional

Published
2017
Full Text
View/download PDF

7. TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study

Author

Sinn, M., primary, Budczies, J., additional, Damm, F., additional, Lohneis, P., additional, Schmuck, R., additional, Treue, D., additional, Striefler, J.K., additional, Bahra, M., additional, Pelzer, U., additional, Jühling, A., additional, Bläker, H., additional, Bischoff, S., additional, Oettle, H., additional, Denkert, C., additional, Riess, H., additional, and Sinn, B., additional

Published
2017
Full Text
View/download PDF

8. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial

Author

Sinn, M., primary, Riess, H., additional, Sinn, B.V., additional, Stieler, J.M., additional, Pelzer, U., additional, Striefler, J.K., additional, Oettle, H., additional, Bahra, M., additional, Denkert, C., additional, Bläker, H., additional, and Lohneis, P., additional

Published
2015
Full Text
View/download PDF

10. Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer

Author

Sinn, M., primary, Liersch, T., additional, Gellert, K., additional, Riess, H., additional, Stübs, P., additional, Waldschmidt, D.T., additional, Pelzer, U., additional, Stieler, J., additional, Striefler, J.K., additional, Bahra, M., additional, Dörken, B., additional, and Oettle, H., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results